logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10808018 B1

PDFFull Text
Date of Patent:
Oct. 20, 2020

Filed:

Aug. 26, 2019

Erythropoietin-derived peptides and methods of protecting cells from oxidative damage induced by reactive oxygen species

Applicant:

Sylus Co., Ltd., Jeonju-si, Jeollabuk-do, KR;

Inventors:

Che il Moon, Daegu, KR;

Seung Yoo, Gyeongsan-si, KR;

Chang-Hun Lee, Daegu, KR;

So Kim, Daegu, KR;

Deok Lee, Ansan-si, KR;

Assignee:

SYLUS CO., LTD., Jeollabuk-Do, KR;

Attorney:

Cantor Colburn LLP

Primary Examiner:

Chang-Yu Wang

Int. Cl.
CPC ...
C07K 2/00 (2006.01); C07K 4/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 14/00 (2006.01); C07K 14/475 (2006.01); C07K 14/48 (2006.01); A61K 38/18 (2006.01); A61K 38/00 (2006.01); A61K 49/00 (2006.01); G01N 33/53 (2006.01); G01N 33/567 (2006.01); C07K 14/505 (2006.01); C12N 15/86 (2006.01); C07K 14/47 (2006.01); A61P 25/28 (2006.01); A61P 25/02 (2006.01); A61P 21/00 (2006.01); A61P 25/00 (2006.01); A61P 9/00 (2006.01); G01N 33/50 (2006.01); C07K 14/71 (2006.01); A61K 38/17 (2006.01); G01N 33/68 (2006.01); A61K 47/64 (2017.01); A61K 39/00 (2006.01); A61P 9/10 (2006.01); C12P 21/02 (2006.01); C07K 14/435 (2006.01); C12N 15/85 (2006.01); C07K 7/08 (2006.01);
U.S. Cl.
CPC ...
C07K 14/505 (2013.01); A61K 38/1816 (2013.01); C07K 14/4702 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 38/179 (2013.01); A61K 38/1709 (2013.01); A61K 47/64 (2017.08); A61K 2039/55516 (2013.01); A61K 2039/6031 (2013.01); A61K 2300/00 (2013.01); A61P 9/00 (2018.01); A61P 9/10 (2018.01); A61P 21/00 (2018.01); A61P 25/00 (2018.01); A61P 25/02 (2018.01); A61P 25/28 (2018.01); C07K 7/08 (2013.01); C07K 14/435 (2013.01); C07K 14/47 (2013.01); C07K 14/4705 (2013.01); C07K 14/71 (2013.01); C07K 2319/00 (2013.01); C07K 2319/70 (2013.01); C12N 15/85 (2013.01); C12P 21/02 (2013.01); G01N 33/5005 (2013.01); G01N 33/5044 (2013.01); G01N 33/5058 (2013.01); G01N 33/68 (2013.01); G01N 2800/52 (2013.01);
Abstract

A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage.

Find Patent Forward Citations

Loading…